Physician profile
Loisann Stapleton
NPI 1811995574
$3,454.95
in general payments reported to CMS, 2019-2025
22 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $389 · 2022: $829 · 2023: $618 · 2024: $1,304 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,197 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,196.71 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $502.67 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $454.20 | 2021-2025 | Wainua, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $376.98 | 2021-2024 | Jardiance |
| Cvrx, INC. | $340.00 | 2021-2024 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $250.70 | 2023-2025 | |
| Boston Scientific Corporation | $247.24 | 2021-2025 | Watchman Flx |
| Pfizer INC. | $197.36 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $188.10 | 2021-2024 | Eliquis, Camzyos |
| Novo Nordisk INC | $145.37 | 2021-2023 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $141.83 | 2025 | |
| Medtronic, INC. | $140.00 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $123.98 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $91.41 | 2022-2024 | Zio Monitor, Zio Xt Patch |
| Abbott Laboratories | $70.04 | 2022 | |
| Amarin Pharma, INC. | $52.04 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $44.00 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $16.96 | 2023 | Uptravi, Opsumit |
| Scpharmaceuticals INC. | $16.58 | 2023 | |
| Bridgebio Pharma, INC. | $15.77 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $13.46 | 2023 | Onpattro |
| Kowa Pharmaceuticals America, INC. | $13.24 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $13.02 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loisann Stapleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.